| | |  | | | | Record from Web of Science® | | | | | | |
| TRANSPLANTATION OF ALLOGENEIC PERIPHERAL-BLOOD STEM-CELLS MOBILIZED BY RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR |
|
|
| Author(s): BENSINGER WI, WEAVER CH, APPELBAUM FR, ROWLEY S, DEMIRER T, SANDERS J, STORB R, BUCKNER CD |
| Source: BLOOD Volume: 85 Issue: 6 Pages: 1655-1658 Published: MAR 15 1995 |
| Times Cited: 493 References: 19 |
| Abstract: Peripheral blood stem cells (PBSCs) are widely used in autologous transplantation because of ease of collection and rapid hematopoietic reconstitution. However, PBSCs have rarely been used for allogeneic transplantation because of concerns about donor toxicities from cytokine administration and the theoretical increased risk of graft-versus-host-disease (GVHD) from the large number of T cells infused. Eight patients with advanced malignancies received allogeneic PBSC transplants from genotypically HLA-identical sibling donors. All donors received 5 days of recombinant human granulocyte colony-stimulating factor (rhG-CSF; 16 mu g/ kg/day) subcutaneously and were leukapheresed for 2 days. After treatment of the patient with total body irradiation and cyclophosphamide (n = 7) or etoposide, thiotepa. and cyclophosphamide (n = 1), PBSCs were infused immediately after collection and without modification. All patients received cyclosporine and either methotrexate (n = 6) or prednisone (n = 2) for GVHD prophylaxis. rhG-CSF was well tolerated with mild bone pain requiring acetaminophen occurring in two donors. All patients engrafted and in seven hematopoietic recovery was rapid, with 500 neutrophils/mu l achieved by day 18 and 20,000 platelets/mu L by day 12. Complete donor engraftment was documented by Y chromosome analysis in ail four sex-mismatched donor-recipient pairs tested and by DNA analysis in two sex-matched pairs. One patient died on day 18 of veno-occlusive disease of the liver with engraftment but before chromosome analysis could be performed (results are pending in 1 patient). A second patient died of fungal infection 78 days after transplant. Grade 2 acute GVHD occurred in two patients and grade 3 GVHD occurred in one patient. One patient is 301 days from transplant in remission with chronic GVHD; the remaining five patients are alive and disease free 67 to 112 days after transplantation. Preliminary results indicate that allogeneic PBSCs mobilized by rhG-CSF can provide rapid hematologic recovery without an appreciably greater incidence of acute GVHD than would be expected with marrow. Further followup is required to determine the incidence of chronic GVHD and any potential beneficial effects on relapse after transplant. (C) 1995 by The American Society of Hematology. |
| Document Type: Article |
| Language: English |
| Reprint Address: BENSINGER, WI (reprint author), UNIV WASHINGTON, FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98195 USA |
Addresses:
1. UNIV WASHINGTON, DEPT MED & PEDIAT, SEATTLE, WA 98195 USA |
| Publisher: W B SAUNDERS CO, INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 |
| Subject Category: Hematology |
| IDS Number: QN289 |
| ISSN: 0006-4971 |
|
| | | | | | | | | Record from Web of Science® | | | | | | | | | |